Overview

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Status:
NOT_YET_RECRUITING

Trial end date:
2032-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Phase:

PHASE4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Standard of Care
Tirzepatide